Avila Therapeutics Appoints Katrine S. Bosley as Company's First CEO.WALTHAM, Mass. -- Avila Therapeutics, an emerging biopharmaceutical company developing a revolutionary new class of medicines known as covalent co·va·lent adj. Of or relating to a chemical bond characterized by one or more pairs of shared electrons. drugs, announced today that Katrine S. Bosley has been appointed as Chief Executive Officer. Ms. Bosley is a biotechnology executive experienced in corporate development of emerging and established biopharmaceutical companies and joins Avila as it advances its business strategy, product pipeline, and proprietary platform. "This is an exceptionally exciting time for Avila as we drive our lead programs towards the clinic and demonstrate the power of our covalent approach against important therapeutic targets," said Daniel S Daniel, book of the Bible Daniel, book of the Bible. It combines "court" tales, perhaps originating from the 6th cent. B.C., and a series of apocalyptic visions arising from the time of the Maccabean emergency (167–164 B.C. . Lynch, Executive Chairman. "Katrine brings a proven record of achievement as a biotechnology executive. Her skills and experience are ideally suited to lead Avila through our next stage of growth as we advance our own products and as we develop strategic alliances to maximize the breadth of our proprietary protein silencing technology." "Avila's focus on the design and development of covalent drugs is an area that has been only modestly explored by traditional pharmaceutical companies. This has given us a very broad set of unique product opportunities," commented Katrine Bosley, Chief Executive Officer. "We've shown with our lead programs that we can deliver products with novel pharmacologic profiles that have the potential to provide unprecedented therapeutic benefits for patients. Furthermore, our strong investor base and experienced leadership team bring to bear the resources and expertise necessary to successfully advance our pipeline." Ms. Bosley joins Avila from Adnexus where she served as Vice President, Business Development and later as VP, Strategic Operations, establishing an alliance with and subsequent acquisition by Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were . During her career she has worked with products from discovery through commercialization, including Avonex[R], Tysabri[R], and the emerging Adnectin[TM] class of targeted biologics. Ms. Bosley was at Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec for many years where she held leadership roles in business development, commercial operations, and portfolio strategy in both the U.S. and Europe. She also held positions at Highland Capital Partners Highland Capital Partners is a global venture capital firm with offices located in Boston, Silicon Valley, Geneva, and Shanghai. Since its inception in 1988, the firm has invested in more than 180 early and growth stage companies and taken a sector-focused approach to investing in , a venture capital firm, and Alkermes, a drug delivery company. Ms. Bosley is a graduate of Cornell University Cornell University, mainly at Ithaca, N.Y.; with land-grant, state, and private support; coeducational; chartered 1865, opened 1868. It was named for Ezra Cornell, who donated $500,000 and a tract of land. With the help of state senator Andrew D. . About Avila Therapeutics Avila Therapeutics is developing a new therapeutic approach called 'protein silencing' based on a proprietary platform for developing covalent drugs that strongly and resiliently bond to disease-causing proteins, resulting in drugs that can be highly effective. Avila's covalent drugs have the potential to deliver unique therapeutic benefits because they are highly targeted, are effective against mutations, and have long duration of action. Avila is developing a pipeline of novel, protein silencing drugs with a current focus on viral infection viral infection, n an infection by a pathogenic virus. A virus acts on the cell nucleus, taking over the genetic material within the nucleus and replicating itself. , cancer, and autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause . Avila is funded by four leading venture capital firms Name Location Founding date Managing Partners/Directors Specialty Capital managed 5AM Ventures Menlo Park, CA; Waltham, MA 2002 John Diekman, PhD (managing partner), Scott Rocklage, PhD (managing partner), Andrew Schwab (managing partner) life sciences $200M [1] : Abingworth, Advent Venture Partners, Atlas Ventures, and Polaris Venture Partners. For additional information, please visit http://www.avilatx.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion